

SECURITIES AND EXCHANGE COMMISSION

FORM CT ORDER

Confidential treatment order

Filing Date: **2013-03-04**
SEC Accession No. [999999997-13-001612](#)

([HTML Version](#) on [secdatabase.com](#))

FILER

HYPERION THERAPEUTICS INC

CIK: **1386858** | IRS No.: **611512713** | State of Incorpor.: **DE** | Fiscal Year End: **1231**
Type: **CT ORDER** | Act: **34** | File No.: **001-35614** | Film No.: **13661843**
SIC: **2834** Pharmaceutical preparations

Mailing Address

601 GATEWAY BLVD.
SUITE 200
SOUTH SAN FRANCISCO CA
94080

Business Address

601 GATEWAY BLVD.
SUITE 200
SOUTH SAN FRANCISCO CA
94080
650-745-7802

**UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
March 4, 2013**

**ORDER GRANTING CONFIDENTIAL TREATMENT
UNDER THE SECURITIES EXCHANGE ACT OF 1934**

Hyperion Therapeutics, Inc.

File No. 1-35614 - CF#29323

Hyperion Therapeutics, Inc. submitted an application under Rule 24b-2 requesting confidential treatment for information it excluded from the Exhibits to a Form 8-K filed on February 20, 2013.

Based on representations by Hyperion Therapeutics, Inc. that this information qualifies as confidential commercial or financial information under the Freedom of Information Act, 5 U.S.C. 552(b)(4), the Division of Corporation Finance has determined not to publicly disclose it. Accordingly, excluded information from the following exhibit(s) will not be released to the public for the time period(s) specified:

Exhibit 10.1 through February 20, 2015

For the Commission, by the Division of Corporation Finance, pursuant to delegated authority:

Jennifer Riegel
Special Counsel